Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Adrian T Gonon"'
Autor:
Attila Kiss, Yahor Tratsiakovich, Adrian T Gonon, Olga Fedotovskaya, Johanna T Lanner, Daniel C Andersson, Jiangning Yang, John Pernow
Publikováno v:
PLoS ONE, Vol 9, Iss 8, p e104731 (2014)
BackgroundPharmacological inhibition of arginase and remote ischemic perconditioning (RIPerc) are known to protect the heart against ischemia/reperfusion (IR) injury.PurposeThe objective of this study was to investigate whether (1) peroxynitrite-medi
Externí odkaz:
https://doaj.org/article/fe42dbfb91644a5886c56ed405310d20
Autor:
Adrian T Gonon, Christian Jung, Abram Katz, Håkan Westerblad, Alexey Shemyakin, Per-Ove Sjöquist, Jon O Lundberg, John Pernow
Publikováno v:
PLoS ONE, Vol 7, Iss 7, p e42038 (2012)
Consumption of L-arginine contributes to reduced bioavailability of nitric oxide (NO) that is critical for the development of ischemia-reperfusion injury. The aim of the study was to determine myocardial arginase expression and activity in ischemic-r
Externí odkaz:
https://doaj.org/article/265ebed166a54d82b607f37b40210be2
Autor:
Adrian T. Gonon, Rodrigo Fernandez-Gonzalo, Michael Melin, Thomas Gustafsson, Eric Rullman, Mirko Mandić
Publikováno v:
Clinical Research in Cardiology
Background Multiple circulatory factors are increased in heart failure (HF). Many have been linked to cardiac and/or skeletal muscle tissue processes, which in turn might influence physical activity and/or capacity during HF. This study aimed to prov
Autor:
Gaio Paradossi, Eddie Weitzberg, Adrian T. Gonon, Johan Härmark, Dmitry Grishenkov, Birgitta Janerot-Sjöberg, Jon O. Lundberg, Barbara Cerroni
Publikováno v:
Drug Design, Development and Therapy
Drug Design, Development and Therapy, Vol 2015, Iss default, Pp 2409-2419 (2015)
Drug Design, Development and Therapy, Vol 2015, Iss default, Pp 2409-2419 (2015)
Dmitry Grishenkov,1–3 Adrian Gonon,3,4 Eddie Weitzberg,5 Jon O Lundberg,5 Johan Harmark,6 Barbara Cerroni,7 Gaio Paradossi,7 Birgitta Janerot-Sjoberg1–3 1Department of Clinical Science, Intervention, and Technology, Karolinska Institutet, Stockho
Autor:
Jiangning Yang, John Pernow, Adrian T. Gonon, Ali Mahdi, Yahor Tratsiakovich, Attila Kiss, Bruno K. Podesser
Publikováno v:
Acta physiologica (Oxford, England). 221(3)
Aims Vagal nerve stimulation (VNS) protects from myocardial and vascular injury following myocardial ischaemia and reperfusion (IR) via a mechanism involving activation of alpha-7 nicotinic acetylcholine receptor (α7 nAChR) and reduced inflammation.
Publikováno v:
PLoS ONE, Vol 11, Iss 4, p e0153036 (2016)
PLoS ONE
PLoS ONE
Aims Patients with heart failure often display a distinct pattern of walking characterized by short step-length and frequent short pauses. In the current study we sought to explore if qualitative aspects of movement have any additive value to establi
Publikováno v:
Clinical physiology and functional imaging. 38(1)
Summary Enhanced external counterpulsation (EECP) is a non-invasive treatment in which leg cuff compressions increase diastolic aortic pressure and coronary perfusion. EECP is offered to patients with refractory angina pectoris and increases physical
Publikováno v:
Diabetologia. 55:600-607
Endothelial dysfunction is important in the development of vascular complications in diabetes. Patients with type 2 diabetes have increased production of the vasoconstrictor and pro-inflammatory peptide, endothelin-1. Short-term intra-arterial admini
Publikováno v:
Acta Physiologica. 201:219-226
Aim: To investigate whether ischaemic post-conditioning (IPoC) combined with i.v. infusion of the nitric oxide (NO) substrate l-arginine at the onset of reperfusion exerts cardioprotective effect that is superior to either treatment given separately.
Publikováno v:
British Journal of Pharmacology. 144:860-866
1 Endothelin (ET) receptor antagonists are cardioprotective during myocardial ischaemia and reperfusion through a nitric oxide (NO)-dependent mechanism. The aim of the present study was to investigate whether the ET receptor antagonist, bosentan, is